OBJECTIVE: To examine the effect of mild renal dysfunction on coronary artery calcifications. METHODS: We examined the progression of coronary atherosclerosis, as measured by dual-section spiral computed tomography, using the total coronary artery calcium score as a quantitative measure of the burden of atherosclerosis. Of 547 high-risk Israeli hypertensive patients, who were participants of the prospective calcification study (a side-arm of the international INSIGHT study), 313 patients completed the 3-year follow-up. Subjects were studied upon entry (on placebo) and again after 3 years of treatment (nifedipine or thiazide). Patients were divided into two groups depending on their creatinine clearance: (i) </= 60 ml/min, renal dysfunction (RD) (n = 53) and (ii) > 60 ml/min, normal renal function group (n = 263). RESULTS:Blood pressure, hypercholesterolemia, and smoking did not differ between the groups. After 3 years of treatment, blood pressure control was similar, whereas the total coronary artery calcium score progression was two-fold greater in the RD than the normal group (156 +/- 32 versus 64 +/- 8, respectively) (P = 0.006). In a multiple logistic regression analysis, the odds ratio (OR) for total coronary artery calcium score progression was higher for the RD group (2.1) [95% confidence interval (CI) 1.2-3.7]. Gender, body mass index, smoking, cholesterol, family history of ischaemic heart disease and diabetes were not significant predictors. Thiazide-based antihypertensive therapy predicted a faster progression compared to nifedipine (OR 1.66, 95% CI 1.09-2.51). CONCLUSIONS: Mild renal dysfunction accelerates coronary artery calcifications, above and beyond conventional risk factors.
RCT Entities:
OBJECTIVE: To examine the effect of mild renal dysfunction on coronary artery calcifications. METHODS: We examined the progression of coronary atherosclerosis, as measured by dual-section spiral computed tomography, using the total coronary artery calcium score as a quantitative measure of the burden of atherosclerosis. Of 547 high-risk Israeli hypertensivepatients, who were participants of the prospective calcification study (a side-arm of the international INSIGHT study), 313 patients completed the 3-year follow-up. Subjects were studied upon entry (on placebo) and again after 3 years of treatment (nifedipine or thiazide). Patients were divided into two groups depending on their creatinine clearance: (i) </= 60 ml/min, renal dysfunction (RD) (n = 53) and (ii) > 60 ml/min, normal renal function group (n = 263). RESULTS: Blood pressure, hypercholesterolemia, and smoking did not differ between the groups. After 3 years of treatment, blood pressure control was similar, whereas the total coronary artery calcium score progression was two-fold greater in the RD than the normal group (156 +/- 32 versus 64 +/- 8, respectively) (P = 0.006). In a multiple logistic regression analysis, the odds ratio (OR) for total coronary artery calcium score progression was higher for the RD group (2.1) [95% confidence interval (CI) 1.2-3.7]. Gender, body mass index, smoking, cholesterol, family history of ischaemic heart disease and diabetes were not significant predictors. Thiazide-based antihypertensive therapy predicted a faster progression compared to nifedipine (OR 1.66, 95% CI 1.09-2.51). CONCLUSIONS: Mild renal dysfunction accelerates coronary artery calcifications, above and beyond conventional risk factors.
Authors: Matthijs Oudkerk; Arthur E Stillman; Sandra S Halliburton; Willi A Kalender; Stefan Möhlenkamp; Cynthia H McCollough; Rozemarijn Vliegenthart; Leslee J Shaw; William Stanford; Allen J Taylor; Peter M A van Ooijen; Lewis Wexler; Paolo Raggi Journal: Eur Radiol Date: 2008-07-24 Impact factor: 5.315
Authors: María M Adeva-Andany; Carlos Fernández-Fernández; Lucía Adeva-Contreras; Natalia Carneiro-Freire; Alberto Domínguez-Montero; David Mouriño-Bayolo Journal: Curr Cardiol Rev Date: 2021
Authors: Matthijs Oudkerk; Arthur E Stillman; Sandra S Halliburton; Willi A Kalender; Stefan Möhlenkamp; Cynthia H McCollough; Rozemarijn Vliegenthart; Leslee J Shaw; William Stanford; Allen J Taylor; Peter M A van Ooijen; Lewis Wexler; Paolo Raggi Journal: Int J Cardiovasc Imaging Date: 2008-05-27 Impact factor: 2.357